About Us
OUR SCIENCE
ESG
투자정보
Contact Us
CONTACT US
A Better Tomorrow with HanAll
Innovative Therapeutics to Address Unmet Medical Needs of Patients
Developing Innovations for Healthier,Longer lives for Patients
Committed to Pioneering NextGeneration Technology
Statement on HL161 Licensing Agreement Termination Notificat..
HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company..
HanAll Biopharma Announces Orphan Drug Designation for Batoc..
- Batoclimab receives Orphan Drug Designation in Japan, advancing treatment for..
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmac..
- HL192 (ATH-399A) was well tolerated with no major safety issues in any of the..
HanAll Biopharma Reports Q3 2024 Financial Results and Prov..
-HanAll records revenue of 36.8 billion KRW in the third quarter, with an opera..
HanAll Biopharma Reports Q2 2024 Financial Results and Provi..
- HanAll reports strong financial performance with second quarter total revenue..
HanAll Biopharma Appoints Christopher W Slavinsky as Chief B..
HanAll Biopharma (KRX: 009420.KS) announced today the appointment of Christophe..
HanAll Biopharma Signs Licensing Agreement with Turn Biotech..
- Exclusive agreement allows HanAll to utilize Epigenetic Reprogramming of Agin..
HanAll Biopharma Announces Initiation of Phase III Randomize..
- HanAll has initiated a Phase III VELOS-4 study to evaluate the efficacy and ..